



Topics

- Defining CVID
- Does it matter what you call it?
- Phenotypes, complications and morbidity
- Laboratory markers
- Genetic tests
- Treatment?
- Inflammatory disease
- But why?





Coming soon: next update from the IUIS committee

J Clin Immunol DOI 10.1007/s10875-015-0201-1

ORIGINAL RESEARCH

Primary Immunodeficiency Diseases: an Update on the Classification from the International Union of Immunological Societies Expert Committee for Primary Immunodeficiency 2015

Capucine Picard¹² • Waleed Al-Herz^{3,4} • Aziz Bousfiha⁵ • Jean-Laurent Casanova^{1,6,7,8,9} • Talal Chatila¹⁰ • Mary Ellen Conley⁶ • Charlotte Cunningham-Rundles¹¹ • Amos Etzioni¹² • Steven M. Holland¹³ • Christoph Klein¹⁴ • Shigeaki Nonoyama¹⁵ • Hans D. Ochs¹⁶ • Eric Oksenhendler^{17,18} • Jennifer M. Puck¹⁹ • Kathleen E. Sullivan²⁰ • Mimi L K. Tang^{21,22,23} • Jose Luis Franco²⁴ • H. Bobby Gaspar²⁵ J Clin Immunol (2015) 35:727-738 DOI 10.1007/s10875-015-0198-5

ORIGINAL RESEARCH

The 2015 IUIS Phenotypic Classification for Primary Immunodeficiencies

Aziz Bousfiha¹ • Leila Jeddane¹ • Waleed Al-Herz²³ • Fatima Aila¹ • Jean-Laurent Casanova^{45,6,73} • Talal Chatlia⁹ • Mary Ellen Conley⁴ • Charlotte Cunningham-Rundles¹⁰ • Amos Etzioni¹¹ • Jose Luis Franco¹² • H. Bobby Gaspar¹³ • Steven M. Holland¹⁴ • Christoph Klein¹⁵ • Shigeaki Nonoyama¹⁶ • Hans D. Ochs¹⁷ • Eric Oksenhendler^{18,19} • Capucine Picard⁵²⁰ • Jennifer M. Puck²¹ • Kathleen E. Sullivan²² • Mimi L. K. Tang^{23,3425}

. Combined immunodeficiencies with a	ssociated or syndromic features
. Predominantly Antibody Deficiencies	·
. Diseases of Immune Dysregulation	
. Congenital defects of phagocyte numl	ber or function
. Defects in Intrinsic and Innate Immun	ity
. Auto-inflammatory Disorders	
. Complement Deficiencies	
. Phenocopies of Inborn Errors of Immu	unity

	IUIS Classifications
1.	Immunodeficiencies affecting cellular and humoral immunity
2.	Combined immunodeficiencies with associated or syndromic features
3.	Predominantly Antibody Deficiencies
	Severe Reduction in All Serum Immunoglobulin Isotypes
	Severe Reduction in at Least 2 Serum Immunoglobulin Isotypes with low or nl B cells
	Severe Reduction in IgG and IgA with Normal/Elevated IgM
	Isotype, Light Chain, with Normal Number B Cells
4.	Diseases of Immune Dysregulation
5.	Congenital defects of phagocyte number or function
6.	Defects in Intrinsic and Innate Immunity
7.	Auto-inflammatory Disorders
8.	Complement Deficiencies
9.	Phenocopies of Inborn Errors of Immunity

ESID workshop criteria for CVID

At least one of the following:

- 1. increased susceptibility to infection
- 2. autoimmune manifestations
- 3. granulomatous disease
- 4. unexplained polyclonal lymphoproliferation
- 5. affected family member

AND marked decrease of IgG and marked decrease of IgA with or without low IgM levels (measured at least twice; <2SD of the normal levels for their age);


AND at least one of the following:


- 1. poor antibody response to vaccines (and/or absent isohaemagglutinins); i.e. absence of protective levels despite vaccination where defined
- 2. low switched memory B cells (<70% of age-related normal value)


AND secondary causes of hypogammaglobulinaemia have been excluded AND diagnosis is established after the 4th year of life (but symptoms may be present before)


AND no evidence of profound T-cell deficiency, defined as 2 out of the following (y = year of life):

- 1. CD4 numbers/microliter: 2-6y <300, 6-12y <250, >12y <200
- 2. % naive CD4: 2-6y <25%, 6-16y <20%, >16y













Fully Adjusted Complic		onal Hazards ated to morto					
Clinical	Hazard Ratio	95% CI	P-value				
Infections only	0.091	[0.029, 0.287]	<0.0001 *				
Autoimmunity	1.351	[0.866, 2.107]	0.1853				
Cancer	1.499	[0.788, 2.851]	0.2168				
Lymphoma	<mark>2.402</mark>	[1.401, 4.117]	0.0014 *				
Hepatitis	2.537	[1.539, 4.184]	<mark>0.0003 *</mark>				
Lung Disease	2.091	[1.360, 3.216]	<mark>0.0008 *</mark>				
Bronchiectasis	0.760	[0.392, 1.470]	0.4129				
Malabsorption	<mark>2.026</mark>	[1.093, 3.757]	<mark>0.0250 *</mark>				
Gastrointestinal Disease	<mark>1.765</mark>	[<u>1.062, 2.934]</u>	<mark>0.0285 *</mark>				
Granuloma	1.258	[0.642, 2.464]	0.5041				
Splenectomy	1.673	[0.905, 3.094]	0.1009				
L	Resnick et al, Blood: 201						




IgG= 54; IgA= 1; IgM= 4











Fully Adjusted Compl		onal Hazards lated to morta	0
Clinical	Hazard Ratio	95% CI	P-value
Infections only	<mark>0.091</mark>	[0.029, 0.287]	<0.0001 *
Autoimmunity	1.351	[0.866, 2.107]	0.1853
Cancer	1.499	[0.788, 2.851]	0.2168
Lymphoma	<mark>2.402</mark>	[1.401, 4.117]	0.0014 *
Hepatitis	<mark>2.537</mark>	[<u>1.539, 4.184]</u>	0.0003 *
Lung Disease	<mark>2.091</mark>	[1.360, 3.216]	0.0008 *
Bronchiectasis	0.760	[0.392, 1.470]	0.4129
Malabsorption	<mark>2.026</mark>	[1.093, 3.757]	0.0250 *
Gastrointestinal Disease	<mark>1.765</mark>	[1.062, 2.934]	0.0285 *
Granuloma	1.258	[0.642, 2.464]	0.5041
Splenectomy	1.673	[0.905, 3.094]	0.1009
	1	Re	snick et al, Blood: 2012
















CVID ILD is part of ge	neralized i	mmune dy	sregulation
Bronchiectasis Pulmonary Nodules Pulmonary Codules Pulmonary Nodules Pulmonary Nodules	bodules Bronch patient (5 or more ILD res - pres - you - mor (CTLA	iectasis was for s with CT evide e pulmonary nodules, sults from immur sent at diagnosis nger CVID patien nogenic "CVID-lil -4 haploinsufficie elta and STAT3 o	ence of ILD ground glass opacity) ne dysregulation s in most cases nts ke" disorders ency, LRBA def.,
	ILD	No ILD	P value
Patients, n Patients, n (%), with	39	22	
History of pneumonia	22 (56)	14 (64)	.78
Splenomegaly/splenectomy	24 (63)	2 (9)	<.0001
AIHA/ITP	22 (56)	1 (5)	<.0001
Liver disease	8 (21)	0(0)	.042
Enteropathy	4 (10)	2 (9)	1.00
Maglione et al. 2014. A	nn Allergy Asthma Immu	<i>Inol.</i> 113: 452-9.	
















Fully Adjusted Compl		onal Hazards I lated to morta	•
Clinical	Hazard Ratio	95% CI	P-value
Infections only	0.091	[0.029, 0.287]	<0.0001 *
Autoimmunity	1.351	[0.866, 2.107]	0.1853
Cancer	1.499	[0.788, 2.851]	0.2168
Lymphoma	2.402	1.401, 4.117	0.0014 *
Hepatitis	2.537	[1.539, 4.184]	0.0003 *
Lung Disease	2.091	[1.360, 3.216]	0.0008 *
Bronchiectasis	0.760	[0.392, 1.470]	0.4129
Malabsorption	2.026	[1.093, 3.757]	0.0250 *
Gastrointestinal Disease	<mark>1.765</mark>	[1.062, 2.934]	0.0285 *
Granuloma	1.258	[0.642, 2.464]	0.5041
Splenectomy	1.673	[0.905, 3.094]	0.1009
L	1	Res	nick et al, Blood: 2012
















Ldi	,	nces in CVID cohort = 91)	.5	
	Complications n=47	No Complications n=44	*P-value	
Age	42 yrs (32-49.5)	43 yrs (38.8-55.8)	0.36	
IgG	207.5 mg/dl (94.3-341.5)	202 mg/dl (67.5-352.8)	0.75	
IgA	7 mg/dl (0-15.5)	8 mg/dl (6.0-20.5)	0.12	
lgM	18 mg/dl (6.5-46.0)	22 mg/dl (12-40)	0.99	
<mark>B cell%</mark>	<mark>7%</mark> 0.2-14.5	9.5% 0.1- 13.9	<mark>0.001</mark>	
Isotype switched memory B cells	<mark>0.65%</mark> <mark>0- 1.6</mark>	<mark>1.3%</mark> <mark>0.45-2.4</mark>	<mark>0.001</mark>	
Absolute Lymphocyte	<mark>1100</mark> (800-1600)	<mark>1300</mark> (1100-3100)	<mark>0.03</mark>	
T cells	75% (65.3-82.5)	75% (65.3-82.5)	0.63	
CD4+ T cells	581 (513-816)	579 (336-708)	0.5	


20 year old : IgG 168 mg/dl;	IgA	= 10, 1	[gM= 24. In	nfections only
CD19+ % of total Lymphocytes		11.7	8	2,8-17.4
CD20+ % of total Lymphocytes		11.8	8	3.2-16.8
CD27+ \$ of CD19+ B cells	L	4.8	8	6.3-52.8
CD27+ 1gN+ 1gD+ 1 of CD19+ B cells		3.7	8	1,7-29,3
CD27+ IgN- IgD- % of CD19+ B cells	ե	0.5	1	2.3-26.5
CD27+ IgH+ IgD- % of CD19+ B cells		0.3	8	0.0-5.3
IgH+ % of CD19+ B cells	я	88.8	8	26.0-78.0
CD38+ 1gN- 1 of CD19+ B cells	L	2.9	•	4,1-42,2
CD38+ IgN+ & of CD19+ B cells		31.6	5	1.2-50.7
CD21+ % of CD19+ B cells		96.8	6	92.1-99.6
CD21- % of CD19+ B cells		3.4	1	0.2-8.6
CD19+		151.2	cells/mcL	90.0-539.0
CD20+		152.5	cells/mcL	95.0-580.8
CD27+	L	7.3	cells/mcL	18.0-145.0
CD27+ IgM+ IgD+		5.6	cells/mcL	4.0-85.0
CD27+ IgN- IgD-	L	0.8	cells/mcL	7.0-61.0
CD27+ IgH+ IgD=		0.5	cells/mcL	0.0-12.0
IgH+		134.3	cells/mcL	37.0-327.0
CD38+ IgN-	L	4.4	cells/mcl	7.0-153.0
CD38+ IgH+		47.8	cells/mcL	2.0-139.4
CD21+		146.4	cells/mcL	85.0-533.0
TACI expression on B cells no reference range establ				
BAFF-r expression on T cells no reference range establis	shed			


CD19+ % of total Lymphocytes		11.7	8	2,8-17.4
CD20+ % of total Lymphocytes		11.8	1	3.2-16.8
CD27+ % of CD19+ B cells	L	4.8	8	6.3-52.8
CD27+ 1gH+ 1gD+ 1 of CD19+ B cells		3.7	8	1,7-29,3
CD27+ IgH- IgD- % of CD19+ B cells		0.5	1	2.3-26.5
CD27+ IgH+ IgD- % of CD19+ B cells		0,3	1	0.0-5.3
IgN+ % of CD19+ B cells	Я	88.8	•	26.0-78.0
CD38+ 1gN- 1 of CD19+ B cells	L	2.9		4,1-42,2
CD38+ IgN+ % of CD19+ B cells		31.6	9	1.2-50.7
CD21+ % of CD19+ B cells		96.8	6	92.1-99.6
CD21- % of CD19+ B cells		3.4	8	0.2-8.6
CD19+		151.2	cells/mcL	90.0-539.0
CD20+		152,5	cells/mcL	95.0-580.8
CD27+	L	7.3	cells/mcL	18.0-145.0
CD27+ IgM+ IgD+		5,6	cells/mcL	4.0-85.0
CD27+ IgN- IgD-	L	0.8	cells/mcL	7.0-61.0
CD27+ IgN+ IgD-		0.5	cells/mcL	0.0-12.0
IgH+		134.3	cells/mcL	37.0-327.0
CD38+ IgX-	L	4.4	celis/mcl	7.0-153.0
CD38+ IgH+		47.8	cells/mcL	2.0-139.4
CD21+		146.4	cells/mcL	85.0-533.0















19 year old girl with progressive lung disease and enteropathy




Lymphocytic infiltrates
Foci of bronchioltitis obliterans
No organisms
Mixed T and B cell infiltrate with lymphoid nodules
Reactive germinal center changes with mitotic figures
Probable non caseating granuloma
Rare giant cells



IgG= 594; IgA<5, IgM normal GI biopsy: villous atrophy








35 year old woman with autoimmunity and liver disease


- Frequent infections, diagnosed with CVID started on IVIg.
- IgG =20; IgA = <4; IgM=<5
- Immune thrombocytopenia
- Splenectomy;
- Granulomatous autoimmune hepatitis
- Prednisone; methorexate =
- Liver re-biopsied: =Cell Cept + prednisone
- Bronchitis, sinusitis continue; asthma diagnosed:
- CD3 =nl ; CD4= low CD8=increased ,CD56 =high; CD19 = very low
- Liver infiltrate: oligoclonal T cell population LRBA:exon11:c.A1399G:p. M467V
 Diad of liver and lymp failure and 20
 LRBA:exon57:c.C8351G:p. A2784G
- Died of liver and lung failure age 39
































Inflammatory conditions in CVID have been called "Non-infectious" complications.

But are they promoted and/or sustained by microbial infections that cannot be eliminated due to the defective immunity?

Summary

- 1. CVID: an immune syndrome due to many causes
- 2. More of a pure B cell defect in some
- 3. Inflammatory phenotypes in 30-50%
- 4. Lymphoid and granulomatous expansion as a reflection of inflammatory drive
- 5. Innate lymphoid cells as a deleterious compensation?
- 6. Drivers of inflammation?

